Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.38 |
| ▸ | TDO2 | P48775 | 3/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518806 | 0.77 | IDO1 (0.38) | IDO1TDO2CES2CES1DPP4 | |
| SCHEMBL16618692 | 0.77 | IDO1 (0.38) | IDO1TDO2ACP3DPP4 | |
| SCHEMBL10654262 | 0.76 | IDO1 (0.48) | IDO1TDO2CYP2D6LMNA | |
| SCHEMBL7851156 | 0.73 | TACR1 (0.39) | IDO1TDO2CYP2D6LMNAKMT2A | |
| SCHEMBL2061580 | 0.73 | LMNA (0.38) | IDO1TDO2ACP3LMNAMAPK1 | |
| SCHEMBL7636381 | 0.73 | TSHR (0.44) | IDO1TDO2ACP3DPP4 | |
| SCHEMBL1307241 | 0.73 | DPP4 (0.44) | IDO1TDO2DPP4 | |
| SCHEMBL5196720 | 0.73 | IDO1 (0.38) | IDO1TDO2CYP2D6LMNADPP4 | |
| SCHEMBL945729 | 0.72 | IDO1 (0.35) | IDO1TDO2ACP3CYP2D6SRC | |
| SCHEMBL2529459 | 0.72 | CYP2D6 (0.45) | ACP3CYP2D6SRCLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | claimed |
| US-9163023-B2 | Compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-10-20 | — | — | US | claimed |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-07-09 | — | — | US | claimed |
| EP-2877468-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2015-06-03 | — | — | EP | claimed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | claimed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | claimed |
| WO-2014009794-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-01-16 | — | — | WO | claimed |
| US-8609653-B2 | Azaindole compounds and methods for treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | claimed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | claimed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | claimed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | claimed |
| WO-2012102985-A1 | ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | WO | claimed |
| US-7122536-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2006-10-17 | — | — | US | claimed |
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-12-26 | — | — | US | claimed |
| US-5700831-A | INSECTICIDE, NEMATOCIDES, MITICIDES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-12-23 | — | — | US | claimed |
| WO-1997033862-A1 | PESTICIDAL HYDRAZIDE DERIVATIVES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-09-18 | — | — | WO | claimed |
| US-10201558-B2 | Compositions of selenoorganic compounds and methods of use thereof | ALLTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-5700831-A | INSECTICIDE, NEMATOCIDES, MITICIDES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| WO-1997033862-A1 | PESTICIDAL HYDRAZIDE DERIVATIVES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043294-A1 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | CETP, DBI, MTTP | IDO1 3501/4885TDO2 1776/4885CES2 188/4885 |
| US-10201558-B2 | Compositions of selenoorganic compounds and methods of use thereof | PSEN2, PSEN1, BACE1 | IDO1 2134/4885TDO2 4315/4885CES2 1899/4885 |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | IDO1 1438/4885TDO2 1080/4885CES2 806/4885 |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | CCR5, CD4, HAVCR2 | IDO1 2637/4885TDO2 4614/4885CES2 12/4885 |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | IDO1 56/4885TDO2 1358/4885CES2 164/4885 |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | IDO1 301/4885TDO2 4018/4885CES2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.